skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis

Review

(1857) Views  (577) Full article downloads

Authors: J Rosa, M Sabelli, Enrique R Soriano

Published Date August 2010 Volume 2010:3 Pages 25 - 31
DOI: http://dx.doi.org/10.2147/MDER.S7504

J Rosa1,2, M Sabelli1,2, Enrique R Soriano1,2
1Rheumatology Section, Internal Medical Services, Hospital Italiano de Buenos Aires, and Fundacion P.M. Catoggio para el progreso de la Reumatologia; 2University Institute, School of Medicine, Hospital Italiano de Buenos Aires, Argentina

Abstract: A new anti-tumor necrosis factor alpha (TNF-a) inhibitor with a novel mechanism of action has entered phase 3 trials in rheumatoid arthritis (RA). Certolizumab pegol (Cimzia®) is a humanized Fab' antibody fragment against TNF-a with a polyethylene glycol tail that prevents complement-dependent and antibody-dependent cell-mediated cytotoxicity or apoptosis. Four randomized clinical trials have been published so far. Reported results are similar to those published in previous studies with other TNF-a inhibitors, with ACR20, ACR50, and ACR70 responses of around 60%, 40%, and 20%, respectively, when combined with methotrexate and slightly lower when used as monotherapy. Safety was shown to be similar to that seen with TNF-a blockers and some cases of tuberculosis were seen in the trials, stressing the importance of a complete screening in these patients. Although we still need effectiveness and safety data in larger numbers of patients and longer follow-up, this new TNF inhibitor is a welcome addition to our current armamentarium for the treatment of RA.

Keywords: certolizumab pegol, rheumatoid arthritis therapy, biologic therapies






Readers of this article also read:

Optimizing pain control through the use of implantable pumps
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers
Bryan total disc arthroplasty: a replacement disc for cervical disc disease
An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen®
New stent design for use in small coronary arteries during percutaneous coronary intervention
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University